Silacyclic Derivatives of Heteroaromatic Sulfides as Selective
Cholesterol Level Lowering and Vasodilating Agents by Abele, Edgars et al.
Metal BasedDrugs Vol. 8, No. 6, 2002
SILACYCLIC DERIVATIVES OF HETEROAROMATIC SULFIDES AS
SELECTIVE CHOLESTEROL LEVEL LOWERING AND VASODILATING
AGENTS
Edgars Abele, Kira Rubina*, Ramona Abele, Olegs Dzenitis, Pavel Arsenyan,
Juris Popelis, Maris Veveris, Dainuvite Meirena, and Edmunds Lukevics
Latvian Institute ofOrganic Synthesis, 21 Aizkraukles street, Riga, LV-1006, Latvia < kira@osi.lv>
ABSTRACT
Silacyclic derivatives of heteroaromatic sulfides have been prepared by using phase transfer catalytic
(PTC) system thiol / silacyclopropyl iodide / solid K2CO3 / 18-crown-6 / toluene. The target sulfides were
isolated in yields up to 70 %. The S-derivatives of N-methylimidazolyl, benzoxazolyl and 1,3,4-triazolyl
thiols selectively lowered the low density lipoprotein (LDL) level in mice with the high cholesterol diet in
nutrition.
INTRODUCTION
Recently the activity of a wide spectrum of heteroaromatic sulfides on the heart and blood circulatory
system was described [1]. For example, quinoline sulfides exhibit antihypertensive [2-4], vasodilating [2-3],
hypotensive [5, 6], euglicemic and hypolipidemic [7], antithrombotic [8], cardiotonic [9], cardiovascular [10-
12] and cholesterol- [13] and blood sugar lowering [14] activities and may be used in the treatment of
diabetes [15-17] and arthritis [18]. Thiazole and benzothiazole sulfides display vasodilating [19], hypotensive
[20] and antihyperglycemic and antihyperlipidemic [21] activities. Imidazole and benzimidazole sulfides
exhibit vasodilating [22], antihypertensive [23], hypoglycemic [24], antithrombotic [25], cardiotonic [26, 27],
cardiovascular [28], cholesterol [29-31] and blood sugar lowering [32], antidiabetic [33, 34] activities,
increase high density lipoprotein cholesterol over lipid fractions [35] and were used in the treatment of
atherosclerosis [36-39] and osteoarthritis [40]. Triazole sulfides were used in the treatment of high blood
pressure and heart failure [41] and display platelet activator and antithrombotic [42] activities. Oxazole
sulfides exhibit an antihypertensive [43] activity. Indole sulfur derivatives were used in the treatment of
atherosclerosis [44], arthritis [45, 46], diabetic complications [47] and congestive hearth failure [48].
In our previous work the cholesterol level lowering and vasodilating activities of silicon and
germanium containing aliphatic derivatives of heteroaromatic sulfides were studied [1]. The 1-
methylimidazole, benzothiazole and 2-quinoline derivatives exhibited the highest level of activity. The
compounds containing dimethyl(l$-triethylgermylethyl)silylmethyl and dimethyl(l$-
triphenylsilylethyl)silylmethyl substituents were the most active in mice with the high cholesterol diet in
nutrition. It was also shown that aliphatic silyl and germyl 1-methylimidazole derivatives possess a
considerable vasodilating activity.
In continuation of our investigations in the field of cholesterol lowering agents the silacyclic S-
derivatives of N-, O- and S-heterocycles have been synthesized under PTC conditions for the purpose to




tH NMR spectra were recorded on a Varian 200 Mercury instrument (200MHz) using CDCI3 as
solvent and hexamethyldisiloxane (HMDSO) as internal standard. Mass spectra were registered on a GC-MS
HP 6890 (70 eV). GC analysis was performed on a Chrom-5 instrument equipped with a flame-ionization
detector using glass column packed with 5 % OV-101 / Chromosorb W-HP (80-100 mesh) (1.2 m x 3 mm).
1-(3-Iodopropyl)-l-methylsilacyclopentane and 1-(3-iodopropyl)-l-methylsilacyclohexane were obtained by
Grignard reaction [49, 50].
SYNTHESIS OFSILACYCLIC DERIVATIVES OFHETARYL THIOLS. GENERAL PROCEDURE.
Finely powdered dry K2CO3 was added to a mixture of 10 mmol of thiol (1 7), 10 mmol of 1-(3-
iodopropyl)-l-methylsilacyclopentane or 1-(3-iodopropyl)-l-methylsilacyclohexane and 18-crown-6
(lmmol, 264 mg) in 25 ml of toluene. The mixture was refluxed with stirring to achieve the disappearance of
the substrates, filtered over the thin silica gel layer and concentrated under reduced pressure. The residue was
purified by column chromatography using benzene-hexane or benzene-ethyl acetate as eluent.
PHARMACOLOGY
Cholesterol level lowering and vasodilating activities and the acute toxicity of synthesized compounds
were determined as described in Ref. 1.
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RESULTS AND DISCUSSION
CHEMISTRY
A simple method for the preparation of silacyclic derivatives of the N-, O- and S-heterocyclic thiols
was developed. The phase transfer catalytical system solid K2CO3/18-crown-6/toluene was used (Figure 1).
The use of the stronger base (KOH) led to the destruction of the alkylating agents. The aimed substances






The alkylation of sulfides 5 7 simultaneously containing two SH and NH targets of reaction led to













The 1,2,4-triazole thiol isomerised during the alkylation reaction. Two products have been isolated: 1-
[3-(1-methyl- -silacyclopentyl)propyl]-5- {[3-(1-methyl- 1-silacyclopentyl)propyl]thio} 1,2,4-triazole (15a)
in 32% and 3-{ [3-(1-methyl-1-silacyclopentyl)propyl]thio}-4-[3-(1-methyl-1-silacyclopentyl)propyl]- 1,2,4-
triazole (15b) in 34% yield correspondingly.
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Table 1. Synthesis of silacycloallo,l derivatives ofheteroaromatic sulfides 8-14, 15a,b
Thiol ’















The purity of the synthesized compounds was determined by HPLC (<1.5% of impurities). All
substances were mobile oils therefore the elemental analysis was not performed.
The structures and spectral characteristics of synthesized substances are shown in Tables 2 and 3.
PHARMACOLOGY
CHOLESTEROL LEVEL LOWERING ,4CTIVITY
The Table 4 data show the serum lipid level at the end of the experiment. The high cholesterol in
nutrition Cholesterol group showed the marked increase in the total and LDL cholesterol in comparison to
the intact control group. The HDL level in Cholesterol group did not differ from the Intact control group.
It has been found, that 2-{[3-(1-methyl-l-silacyclopentyl)propyl]thio}benzoxazole (9), 3-{[3-(1-
methyl-1-silacyclopentyl)propyl]thio}-4-[3-(1-methyl-1-silacyclopentyl)propyl]-1,2,4-triazole (15b), 1-
methyl-2- { [3-(1-methyl-1-silacyclopentyl)propyl]thio}imidazole (8), and 2-{[3-(1-methyl-1-silacyclopentyl)-
propyl]thio}benzothiazole (10) produced a high antiatherosclerotic activity protected against increase in
serum LDL cholesterol level and atherosclerotic coefficient.
Benzoxazole and triazole derivatives 9 and 15b show the highest activity among all the investigated
aliphatic [1] and silacyclic S-substituted heterocycles. A preliminary analysis of the structure-activity
relationship for the cholesterol lowering action clearly indicates the strong influence of the silacyclic
substituent position in the triazole ring. Compound 15a bearing a silacyclopentyl)propyl group in position
has slight effect on the cholesterol level (K 0.799). On contrary 4-N-substitution leads to a considerable
increasing of activity: 3-{[3-(-methy--siacycpenty)prpy]thi}-4-[3-(-methy--siacycpenty)-
propyl]-l,2,4-triazole (15b) is 9 times more active (K 0.091) than the isomer 15a.
The silacyclic imidazole derivative 8 has better K value (K 0.111) than the corresponding
trimethylsilylpropyl analogue (K--0.453) [1]. Moreover, compound 8 show the tendency to increase the HDL
level. This fact indicates that this compound can possess an additional positive influence.
The activity of the silacyclic substituted benzothiazole 10 (K 0.200) slightly differs from 2-(3-
trimethylsilylpropyl)thiobenzothiazole (K 0.285) [1]. The insertion of a methylene group into the five-
membered silacyclopentane ring leads to decrease of activity (atherogenecity coefficient K=0.200 for 10 and
K=0.401 for 11).
It is significant to note that benzoxazole derivative 9 is 3 times more active than benzothiazole
derivative 10.
V,4SODIL,4TING ,4CTIVITY
The vasodilating activity of the studied compounds in experiments in vivo is presented in the Table 4.
In general the studied silacyclic compounds have a weak influence on vasodilatation even in a 50tag/mL
dose. It was found that imidazole derivative 8 exhibits the highest relaxation effect (18% in 10 lag/mL). It is
more active than aliphatic silicon-containing analogues (12-13%), but less active than dimethyl(l-
triethylgermylethyl)silylmethyl substituted imidazole (22%) ].
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Table 2. IH and 3CNMR data ofheteroaromatic sulfides
Cpd
1H NMR, d (ppm, CDCI3 /HMDSO)
8 0.06 (s, 3H, SiCH3), 0.51 and 0.72 (each m, 6H,
10
11
SiCH2), 1.51 and 1.67 (each m, 6H, CH2), 3.03
(t, 2H, J 7.0 Hz, SCH2), 3.60 (s, 3H, NCH3),
7.91-8.05 (m, 2H, imidazole cycle)
0.08 (s, 3H, SiCH3), 0.53 and 0.78 (each m, 6H,
SiCH2), 1.54 and 1.85 (each m, 6H, CH2), 3.31
(t, 2H, J 7.2 Hz, SCH2), 7.2-7.6 (m, 4H,
benzoxazole cycle)
0.08 (s, 3H, SiCH3), 0.53 and 0.78 (each m, 6H,
SiCH2), 1.54 and 1.85 (each m, 6H, CH2), 3.34
(t, 2H, J 8.0 Hz, SCH2), 7.33 and 7.79 (m, 4H,
benzothiazole cycle)
0.005 (s, 3H, SiCH3, 0.65 (m, 6H, SiCH2), i.64
(m, 8H, CH2), 3.35 (t, 2H, J 7.4 Hz, SCH2),
7.25, 7.74 and 7.87 (m, 4H, benzothiazole cycle)
-12 0.13 (s, 3H, SiCH3), 0.71 (m, 6H, SiCH2), 1.71
(m, 6H, CH2), 3.07 (t, 2H, J 7.0 Hz, SCH2),
7.40, 8.05 and 8.92 (m, 6H, quinoline cycle)
13 -0.01 and 0.00 (both s, 6H, SiCH3), 0.57 (m,
12H, SiCH2), 1.2-1.8 (each m, 16H, CH2), 3.50
(t, 2H, J 7.0 Hz, SCH2), 4.06 (t, 2H, J 7.2 Hz,
NCH2), 7.24 and 7.74 (m, 5H, indole cycle)
li 0.08 and 0.08 (both s, 6H, SiCH3), 0.51-0.83 (m,
15a
12H, SiCH2), 1.54 and 1.82 (each m, 12H, CH2),
3.42 (t, 2H, J 7.2 Hz, SCH2), 4.07 (t, 2H, J
7.4 Hz, NCH2), 7.22 and 7.68 (m, 4H,
benzimidazole cycle)
0.06 and 0.07(each s, 3H, SiCH3), 0.52 and 0.72
(each m, 6H, SiCH2), 1.53 and 1.78 (each m, 6H,
CH2), 3.22 (t, 2H, J 7.4 Hz, SCH2), 4.02 (t, 2H,
J 8.0 Hz, NCH2), 7.84 (s, H, triazole cycle)
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15b 0.05 and 0.07(each s, 3H, SiCH3), 0.52 and 0.73
(each m, 6H, SiCH2), 1.53 and 1.78 (each m, 6H,
CH2), 3.11 (t, 2H, J 7.4 Hz, SCH2), 4.05 (t, 2H,

















Table 3. Mass spectra ofheteroaromatic sulfides
m/z (relative intensity, %)
254 (M*, 5), 225 (40), 207 (14), 197 (29), 183 (35), 170 (34), 157 (51), i41 (31), 114 (100), 99
(23),.83 (15),.71 (31), 59.(19) 43 (34)
291 (M*, 8), 276 (18), 262 (62), 249 (49),’ 234 (62),’ 220’ (100), 207 (85), 194 (48), 178 (40), 167
(13), 146 (69), 133 (57, 122 (64), 99 (89), 91 (18), 83 (15), 71 (100), 59 (50), 43 (.83)
307 (M*, 11) 292 (M -Me, 10), 280 (13), 274 (17), 265 (14), 264 (12), 263 (18), 251 (24), 250
(39), 237 (67), 236 (51), 232 (15), 223 (18), 22 (74), 209 (29), 193 (27), 179 (12), 167 (88), 162
(100), 150 (12), 149 (62), 135 (21), 122 (14), 117 (21), 109 (12), 108 (33), 102 (17), 99 (58), 97
(52), 95 .(13), 75 (28), 69 (26), 59 (44), 45 (76), 43 (72)
321 (M*, 10), 278 (100), 250 (26), 237 (30), 236 (28), 223 (21), 194 (10), 167 (40), 136 (15), 113
(15), 108 (15), 85 (46), 69 (11), 59 (24), 45 (28), 43 (27)
301 (M*, 14), 286 (14), 272 (42), 254 (51), 244 (61), 230 (27), 217 (75), 202 (81), 188 (100), 174
(65), 161 (96), 142 (40), 129 (56), 116 (24), 99 (38), 89 (20), 71 (36), 59 (24), 43 (49)
331 (M*-SiMe(CH2)5, 10), 303 (11), 149 (45), 117 (100), 113 (90), 187 (100), 85 (82), 59 (70)
416 (M*-Me, 5), 415 (14), 304 (8), 261 (31), 248 (37), 234 (13), 191 (9), 150 (25), 113 (38), 85
(1 00), 59 (34), 43 (22)
381 (M*, 21), 380 (M*-I, 6), 351 (18), 340 (18), 324 (10), 310 (12), 298 (18), 284 (15), 282 (14),
264 (12), 242 (42), 212 (17), 210 (14), 200 (35), 186 (17),185 (19), 184 (17), 158 (10), 121 (15),
117 (26), 99 (100), 98 (28), 97. (58),, .85 (15), 71 (78), 59 (35),. 45 (32), 43 (33)
381 (M*, 10), 366 (M*-Me, 10), 353 (20), 325 (60), 344 (26), 339 (16), 325 (18), 324 (32), 320
(14), 305 (16), 292 (18), 282 (16), 268 (12), 242 (15), 240 (15), 226 (16), 212 (27), 200 (15), 186
(16), 170 (15), 142 (15), 128 (10), 117 (34), 99 (100), 97 (64), 85 (20), 71 (85), 59 (32), 45 (27),
43 (3)













high and low density iipoprotein level
and the atherogenicity coefficient (K)
Total cholesterol HDL LDL K mg/dl mg/dl mg/dl
124,7 70,7 54,0 0,825
99,9 90,5 9,5 0,111
75,3 70,2 5,1 0,073
99,7 82,9 16,7 0,200
87,1 61,8 25,3 0,401
80,3 49,2 3 l, 0,726
89,8 77,5 12,3 0,197
88,7 55,2 33,5 0,643
104,9 59,7 45,3 0,799
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Intact
control 69,0 64,9
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50 15
4,1 0,065 Control/ 3 Solvent
ACUTE TOXICITY
The studied compounds have basically a low acute toxicity (Table 4). Only imidazole sulfide
exhibits a medium level oftoxicity (375 mg/kg).
CONCLUSIONS
A PTC method of synthesis of silacyclic derivatives of the N-, O- and S-heterocyclic sulfides was
elaborated. Nine compounds were synthesized and isolated in the yields up to 70%.
They were studied as serum cholesterol level lowering agents. It has been found, that
silacyclopentylpropylthio-imidazole ($), -benzoxazole (9), -benzothiazole (10) and -1,2,4-triazole (15b)
exhibited a high antiatherosclerotic activity. It protected against increase in serum LDL cholesterol level. A
preliminary analysis of the structure-activity relationship for the cholesterol lowering action clearly indicates
the strong influence of the silacyclic substituent position in the triazole ring. Imidazole derivative $ has
shown the tendency to increase the HDL level. This fact indicates that compound can possess an additional
positive influence. The synthesized sulfides are low toxic compounds with weak vasodilating activity.
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